by Andrea Lobo | Feb 17, 2026 | Myeloma News
A new, ultrasensitive blood test checks for cancer cells remaining in the body after multiple myeloma treatment using blood samples instead of more invasive bone marrow biopsies, helping doctors assess relapse risk and monitor treatment response. Quest Diagnostics...
by MM360 Staff | Feb 17, 2026 | Myeloma News
Source: Myeloma : nature.com subject feeds Post Content Read More
by MM360 Staff | Feb 17, 2026 | Myeloma News
Source: Myeloma : nature.com subject feeds Post Content Read More
by Andrea Lobo | Feb 16, 2026 | Myeloma News
Enrollment is now complete for an early clinical study assessing the safety and tolerability of SENTI-202, Senti Biosciences’ cell therapy candidate for adults with hard-to-treat acute myeloid leukemia (AML), a type of blood cancer. The Phase 1 trial (NCT06325748)...
by MM360 Staff | Feb 14, 2026 | Publications
Ther Adv Hematol. 2026 Feb 10;17:20406207261417132. doi: 10.1177/20406207261417132. eCollection 2026. ABSTRACT OBJECTIVE: This systematic literature review analyzed real-world evidence on autologous stem cell transplantation (ASCT) for newly diagnosed multiple myeloma...
